To investigate the efficacy of each of two doses of adefovir compared to placebo with respect to changes in liver histology and in enhancing anti-HBe sero conversion and decreasing serum HBV DNA, at the end of one year and 2 years. Adefovir could potentially have antiviral activity in a broader range of cell types than other nucleoside therapies with antiHBV activity. Previous data suggests that it may be possible to treat lamivudine-resistant strains of HBV with adefovir and that combination therapy of adefovir with lamivudine may prevent the energency of resistance to lamivudine.
Showing the most recent 10 out of 871 publications